



SERES
THERAPEUTICS™

Seres Therapeutics to Host First Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on May 16, 2016

May 9, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 9, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced that management will host a conference call and live audio webcast on Monday, May 16, 2016 at 8:30 a.m. ET to discuss first quarter 2016 results.

To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 8373803. To join the live webcast please visit the "Investors and Media" section of the Seres website at www.serestherapeutics.com.

A webcast replay with corresponding slides will be available on the Seres website beginning approximately two hours after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome characterized by an increased presence of pathogenic bacterial species, where the natural state of bacterial diversity is imbalanced. Seres' most advanced program, SER-109, has successfully completed a Phase 1b/2 study demonstrating a clinical benefit in patients with recurring *Clostridium difficile* infection (CDI) and is currently being evaluated in a Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug, as well as Breakthrough Therapy, designations. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). For more information, please visit www.serestherapeutics.com. Follow us on Twitter @SeresTx.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20160509005430/en/>

Source: Seres Therapeutics, Inc.

IR and PR Contact:

Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com